Necitumumab Not Effective for Non-EGFR-expressing NSCLC

Share this content:
As observed in the intention-to-treat analysis of the SQUIRE trial, adding necitumumab to gemcitabine plus cisplatin significantly improved overall survival.
As observed in the intention-to-treat analysis of the SQUIRE trial, adding necitumumab to gemcitabine plus cisplatin significantly improved overall survival.

As observed in the intention-to-treat analysis of the SQUIRE trial, adding necitumumab to gemcitabine plus cisplatin significantly improved overall survival in patients with epidermal growth factor receptor (EGFR)-expressing advanced squamous non-small cell lung cancer (NSCLC), a subgroup analysis published in Annals of Oncology has shown.1 However, patients with non-EGFR-expressing tumors did not benefit from the addition of necitumumab to chemotherapy.

In the phase 3 SQUIRE trial, researchers enrolled 1093 patients with stage IV squamous NSCLC. Of those, 982 had evaluable immunohistochemistry results, and 95% had tumor samples expressing EGFR protein.

Participants were randomly assigned 1:1 to receive gemcitabine 1250 mg/m² IV on days 1 and 8 and cisplatin 75 mg/m² IV on day 1 with or without necitumumab 800 mg IV on days 1 and 8 for a maximum of 6 3-week cycles. Patients in the chemoimmunotherapy arm who did not experience disease progression continued receiving necitumumab alone until disease progression or unacceptable toxicity.

Results of the subgroup analyses showed that median overall survival was 11.7 months (95% CI, 10.7-12.9) with necitumumab vs 10.0 months (95% CI, 8.9-11.4) without it among patients with EGFR-expressing tumors (HR, 0.79; 95% CI, 0.69-0.92; P = .002).

In contrast, researchers found that in the 5% of patients with tumors without detectable EGFR protein, there was no survival advantage with necitumumab.

RELATED: Navigating the 2016 ASCO Annual Meeting: Immunotherapy, Precision Medicine 'Significant Themes'

Of note, patients with non-EGFR-expressing tumors had a higher incidence of grade 3 or higher hypomagnesemia and rash compared with patients with EGFR-expressing advanced squamous NSCLC.

The U.S. Food and Drug Administration approved the EGFR antagonist in 2015 for first-line treatment of patients with metastatic squamous NSCLC, in combination with gemcitabine and cisplatin. Necitumumab is not indicated for non-squamous NSCLC.

Reference

  1. Paz-Ares L, Socinski MA, Shahidi J, et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer [published online ahead of print May 20, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw214.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs